Therapeutic | Sarilumab |
Target | IL6R/CD126 |
Heavy Chain | EVQLVESGGGLVQPGRSLRLSCAASRFTFDDYAMHWVRQAPGKGLEWVSGISWNSGRIGYADSVKGRFTISRDNAENSLFLQMNGLRAEDTALYYCAKGRDSFDIWGQGTMVTVSS |
Light Chain | DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYGASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFASYYCQQANSFPYTFGQGTKLEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (Aug '24) | Approved |
Estimated Status (Aug '24) | Active |
Recorded Developmental Technology | VelocImmune Mouse |
INN Year Proposed | 2011 |
INN Year Recommended | 2012 |
Companies Involved | Asahi Kasei Pharma Corp, Regeneron Pharmaceuticals, Sanofi |
Conditions Approved | Rheumatoid arthritis |
Conditions Active | Juvenile rheumatoid arthritis |
Conditions Discontinued | Ankylosing spondylitis, COVID-19, Giant cell arteritis, Polymyalgia rheumatica, Uveitis |
Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]